Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in pediatric refractory generalized myasthenia gravis
NL-OMON54896Phase 3Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in myasthenia gravis (MG), generalized myasthenia gravis (gMG), sponsored by Alexion Pharmaceuticals. Planned start Dec 2020; status: withdrawn.
02
Drugs
eculizumab
03
Conditions
myasthenia gravis (MG)generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on NL-OMON54896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54896.